Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Gotlib

Showing results (91-100 of 210) with videos related to

Pageof 21
Sort By:
Blood Advances|January 31, 2018
Variability of PD-L1 expression in mastocytosisEllen W Hatch, Mary Beth Geeze, Cheyenne Martin, et al.
Haematologica|June 13, 2015
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M Vannucchi, Hagop M Kantarjian, Jean-Jacques Kiladjian, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
The Journal of Allergy and Clinical Immunology|April 17, 2022
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022Michel Arock, Gregor Hoermann, Karl Sotlar, et al.
Blood|July 2, 2016
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasmsDavid A Hinds, Kimberly E Barnholt, Ruben A Mesa, et al.
Haematologica|October 4, 2016
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practiceCelalettin Ustun, Michel Arock, Hanneke C Kluin-Nelemans, et al.
Blood|June 18, 2011
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinibKaroline V Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, et al.
Hematological Oncology|April 24, 2019
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasmsTariq I Mughal, Naveen Pemmaraju, Jerald P Radich, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2021
Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitorsLu Cui, Ignacio Moraga, Tristan Lerbs, et al.
Pageof 21

Showing results (91-100 of 210) with videos related to

Sort By:
Pageof 21
Blood Advances|January 31, 2018
Variability of PD-L1 expression in mastocytosisEllen W Hatch, Mary Beth Geeze, Cheyenne Martin, et al.
Haematologica|June 13, 2015
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M Vannucchi, Hagop M Kantarjian, Jean-Jacques Kiladjian, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
The Journal of Allergy and Clinical Immunology|April 17, 2022
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022Michel Arock, Gregor Hoermann, Karl Sotlar, et al.
Blood|July 2, 2016
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasmsDavid A Hinds, Kimberly E Barnholt, Ruben A Mesa, et al.
Haematologica|October 4, 2016
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practiceCelalettin Ustun, Michel Arock, Hanneke C Kluin-Nelemans, et al.
Blood|June 18, 2011
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinibKaroline V Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, et al.
Hematological Oncology|April 24, 2019
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasmsTariq I Mughal, Naveen Pemmaraju, Jerald P Radich, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2021
Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitorsLu Cui, Ignacio Moraga, Tristan Lerbs, et al.
Pageof 21